A compound having the structure of below Formula (I), or pharmaceutically acceptable salts thereof, are useful as JAK inhibitors, ##STR00001##
wherein R.sub.1, R.sub.2, L.sub.1, L.sub.2, T and X are as herein described.

Compositions that modulate the activity of signal transducer and activator of transcription-3 (STAT3) activity as well as their methods of use, such as treatment and imaging are provided. Compositions contain small molecules such as substituted pyrazoles and are useful in treatment of diseases related to the activity of STAT3 including, for example, cancer and other diseases.

Compositions that modulate the activity of signal transducer and activator of transcription-3 (STAT3) activity as well as their methods of use, such as treatment and imaging are provided. Compositions contain small molecules such as substituted pyrazoles and are useful in treatment of diseases related to the activity of STAT3 including, for example, cancer and other diseases.

The invention relates inter alia to compounds of the general formula (I). Also described are methods for preparing the compounds of the formula (I). The compounds according to the invention are especially suitable for controlling insects, arachnids and nematodes in agriculture, and ectoparasites in veterinary medicine and also as herbicides.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

##STR00001##

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

##STR00001##

Hydrotetrazine compounds having antioxidant properties and uses thereof are described herein. These compounds may be dihydrotetrazines, tetrahydrotetrazines, or hexahydrotetrazines that can be utilized as antioxidants for use in thermoplastics, thermosets and elastomers; free radical inhibitors to stabilize reactive chemicals, such as monomers against free radical polymerizations; and as anticorrosion agents in coatings to protect against metal oxidation. The hydrogenated tetrazines can donate hydrogen atom equivalents to terminate radical chain reactions. These compounds can change colors to signal when oxidation has occurred, and can be further recycled by reduction reactions.

Hydrotetrazine compounds having antioxidant properties and uses thereof are described herein. These compounds may be dihydrotetrazines, tetrahydrotetrazines, or hexahydrotetrazines that can be utilized as antioxidants for use in thermoplastics, thermosets and elastomers; free radical inhibitors to stabilize reactive chemicals, such as monomers against free radical polymerizations; and as anticorrosion agents in coatings to protect against metal oxidation. The hydrogenated tetrazines can donate hydrogen atom equivalents to terminate radical chain reactions. These compounds can change colors to signal when oxidation has occurred, and can be further recycled by reduction reactions.

A tetrazolinone compound represented by formula (1): ##STR00001##
wherein R.sup.1 represents a hydrogen atom, a C1-C3 alkyl group optionally having one or more halogen atoms, a C1-C3 alkoxy group optionally having one or more halogen atoms, a halogen atom, a cyano group, or a C1-C3 alkylthio group optionally having one or more halogen atoms; and R.sup.2 represents a C1-C3 alkyl group optionally having one or more halogen atoms, a C1-C3 alkoxy group optionally having one or more halogen atoms, a hydrogen atom, a halogen atom, or a C3-C4 cycloalkyl group optionally having one or more halogen atoms, has excellent control activity against plant diseases.

Compositions and pharmaceutical compositions including one or more selenium-containing COX-2 inhibitors are provided according to aspects of the present invention. Methods of treating a subject having or suspected of having cancer are provided according to aspects of the present invention which include administering a therapeutically effective amount of a pharmaceutical composition including a selenium-containing COX-2 inhibitor.